NASP (previously known as SEL-212) - clinical program overview and uncontrolled gout disease landscape.

STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Investors, analysts, and members of the media are invited to a conference call on Tuesday, 16 September, at 16:30 CEST, 15:30 BST, and 10:30 EDT. The call will present insights from management and Dr. Herbert Baraf on the NASP program, following the US FDA acceptance of the filing submission of NASP for the potential treatment of uncontrolled gout.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13
For other countries, please find the details here.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-nasp-and-uncontrolled-gout-call-and-webcast,c4232532

The following files are available for download:


     
     https://mb.cision.com/Main/14266/4232532/3660322.pdf Invitation Sobis NASP Uncontrolled Gout call
                                                              and webcast

View original content:https://www.prnewswire.co.uk/news-releases/invitation-sobis-nasp-and-uncontrolled-gout-call-and-webcast-302552416.html

Tags

More Like This

FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout

Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call

Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology

Sobi showcases new data across rare inflammatory conditions at ACR 2025

Invitation: Sobi's Q1 2024 report

Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week

Invitation: Sobi's Q2 2024 report

Invitation: Sobi's Q1 report